RT Journal Article
T1 Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
A1 Pajares, Bella
A1 Trigo, José M
A1 Toledo, María D
A1 Álvarez, Martina
A1 González-Hermoso, Carlos
A1 Rueda, Antonio
A1 Medina, José A
A1 Luque, Vanessa de
A1 Jerez, José M
A1 Alba, Emilio
K1 Chemotherapy
K1 EGFR inhibitors
K1 Head and neck cancer
K1 Human papillomavirus
K1 Neoplasias de Cabeza y Cuello
K1 Tomografía de Emisión de Positrones
K1 Radioterapia
K1 Inmunohistoquímica
K1 Reacción en Cadena de la Polimerasa
K1 Factor de Crecimiento Epidérmico
K1 Radioisótopos
K1 Radiofármacos
AB BACKGROUNDHuman papillomavirus (HPV)-related head and neck cancer has been associated with an improved prognosis in patients treated with radiotherapy (RT) +/- chemotherapy (CT); however, RT combined with epidermal growth factor receptor (EGFR) inhibitors has not been fully studied in this group of patients.METHODSImmunohistochemical expression of p16 and PCR of HPV16 DNA were retrospectively analyzed in tumor blocks from 108 stage III/IV head and neck cancer patients treated with RT+CT (56) or RT+EGFR inhibitors (52). Disease-free survival (DFS) and overall survival (OS) were analyzed by the Kaplan-Meier method.RESULTSDNA of HPV16 was found in 12 of 108 tumors (11%) and p16 positivity in 18 tumors (17%), with similar rates in both arms of treatment. After a median follow-up time of 35 months (range 6-135), p16-positive patients treated with RT+EGFR inhibitors showed improved survival compared with those treated with RT+CT (2-year OS 88% vs. 60%, HR 0.18; 95% CI 0.04 to 0.88; p = 0.01; and 2-year DFS 75% vs. 47%, HR 0.17; 95% CI 0.03 to 0.8; p = 0.01). However, no differences were observed in p16-negative patients (2-year OS 56% vs. 53%, HR 0.97; 95% CI 0.55 to 1.7; p = 0.9; and 2-year DFS 43% vs. 45%, HR 0.99; 95% CI 0.57 to 1.7; p = 0.9).CONCLUSIONSThis is the first study to show that p16-positive patients may benefit more from RT+EGFR inhibitors than conventional RT+CT. These results are hypothesis-generating and should be confirmed in prospective trials.
PB BioMed Central
YR 2013
FD 2013-01-18
LK http://hdl.handle.net/10668/1144
UL http://hdl.handle.net/10668/1144
LA en
NO Pajares B, Trigo JM, Toledo MD, Álvarez M, González-Hermoso C, Rueda A, et al. Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer. BMC Cancer. 2013; 13(1):26
NO Journal Article; Research Support, Non-U.S. Gov't;
DS RISalud
RD Apr 10, 2025